Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a
single-arm study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation (EP)
in combination with pembrolizumab therapy. Cohort 2 will be a single-arm study of
intratumoral tavo-EP plus pembrolizumab with nab-paclitaxel (Abraxane®) chemotherapy.
Subjects with TNBC and EP accessible cutaneous / subcutaneous disease will be enrolled in
this study.